CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The main purpose of this study is to evaluate the safety, tolerability, and recommended phase 2 target dose of tarlatamab in combination with AMG 404.
Phase 1
Salt Lake City, Utah, United States and 16 other locations
with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....
Phase 3
Salt Lake City, Utah, United States and 209 other locations
the safety and tolerability of itacitinib in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung...
Phase 1, Phase 2
Salt Lake City, Utah, United States and 30 other locations
with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung ...
Phase 3
Salt Lake City, Utah, United States and 205 other locations
(PK) of BBO-8520, a KRAS G12C (ON) inhibitor, single agent and in combination with pembrolizumab in patients with advanced non-small cell lung...
Phase 1
Salt Lake City, Utah, United States and 10 other locations
osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung...
Phase 3
Salt Lake City, Utah, United States and 117 other locations
of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topotecan or irinotecan) as control arm (Group C), in Small-cell Lung...
Phase 3
Salt Lake City, Utah, United States and 213 other locations
antitumor activity of STX-721 in participants with non-small cell lung cancer (NSCLC) carrying EGFR/HER2 exon 20 insertion (ex20ins...
Phase 1, Phase 2
Salt Lake City, Utah, United States and 14 other locations
(termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays....
Phase 3
Salt Lake City, Utah, United States and 123 other locations
This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously...
Phase 3
Salt Lake City, Utah, United States and 262 other locations
Clinical trials
Research sites
Resources
Legal